We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ARCT market cap is 581.9M. The company's latest EPS is USD -1.0992 and P/E is -19.51.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 10.52M | 45.14M | 33.99M | 38.01M | 49.86M |
Operating Income | -73.25M | -18M | -15.14M | -30.41M | -21.13M |
Net Income | -70.43M | 1.66M | -8.57M | -26.82M | -17.22M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 20.79M | 9.54M | 12.36M | 206M | 166.8M |
Operating Income | -25.55M | -71.79M | -202.34M | 11.66M | -78.21M |
Net Income | -25.99M | -72.15M | -203.67M | 9.35M | -29.73M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 430.65M | 457.65M | 429.4M | 418.85M | 388.61M |
Total Liabilities | 145.47M | 177.59M | 147.76M | 154.88M | 130.03M |
Total Equity | 285.18M | 280.06M | 281.65M | 263.97M | 258.58M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 82.14M | 476.46M | 392.81M | 450.39M | 429.4M |
Total Liabilities | 56.35M | 79.9M | 164.6M | 180.08M | 150.89M |
Total Equity | 25.79M | 396.55M | 228.21M | 270.31M | 278.51M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 14.94M | -17.47M | N/A | -5.56M | -35.7M |
Investing | -1.05M | -2.03M | N/A | -240k | -568k |
Financing | -27.27M | -5.43M | N/A | 2.19M | 4.59M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -6.45M | -42.86M | -135.04M | 31.99M | -18.1M |
Investing | -818k | -1.74M | -3.41M | -7.73M | -2.9M |
Financing | 41.91M | 436.15M | 48.02M | -2.86M | -24.09M |
Market Cap | 581.9M |
Price to Earnings Ratio | -19.51 |
Price to Sales Ratio | 3.48 |
Price to Cash Ratio | 1.99 |
Price to Book Ratio | 2.08 |
Dividend Yield | - |
Shares Outstanding | 27.04M |
Average Volume (1 week) | 267.16k |
Average Volume (1 Month) | 374.36k |
52 Week Change | -13.23% |
52 Week High | 45.00 |
52 Week Low | 17.52 |
Spread (Intraday) | 1.44 (6.67%) |
Company Name | Arcturus Therapeutics Holdings Inc |
Address |
10628 science center drive, suite 250 san diego, california 92121 |
Website | https://arcturusrx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions